Estradiol exerts neuroprotective effects when administered after ischemic insult

Area of Science:

• Neuroscience
• Endocrinology
• Cerebrovascular Research

Background:

• 17beta-Estradiol (E2) is known for neuroprotective effects when administered before ischemic events.
• The efficacy and therapeutic window of E2 treatment initiated after ischemia remain less understood.
• Investigating the impact of post-ischemia E2 on cerebral blood flow (CBF) is crucial.

Purpose of the Study:

• To determine if 17beta-Estradiol (E2) administered after cerebral ischemia offers neuroprotection.
• To establish the duration of the therapeutic window for post-ischemia E2 treatment.
• To examine the relationship between E2 treatment and changes in cerebral blood flow (CBF).

Main Methods:

• Female Sprague-Dawley rats underwent permanent middle cerebral artery occlusion (MCAO).
• E2 was administered intravenously and subcutaneously at varying times (0.5 to 4 hours) post-MCAO.
• Ischemic lesion volume was quantified, and cerebral blood flow (CBF) was monitored in separate cohorts.

Main Results:

• E2 significantly reduced ischemic lesion volume when administered within 3 hours after MCAO.
• Lesion volumes were smallest with E2 administration at 0.5 hours post-MCAO.
• While immediate CBF was unaffected, E2 treatment led to a significant delayed increase in CBF.

Conclusions:

• 17beta-Estradiol (E2) demonstrates significant neuroprotective effects when administered post-ischemia.
• The therapeutic window for E2 in this permanent focal cerebral ischemia model is approximately 3 hours.
• The neuroprotective benefits of E2 are associated with a delayed enhancement of cerebral blood flow (CBF).